Canaccord Genuity initiated coverage on Core Scientific with a new price target
$CORZ
Finance: Consumer Services
Finance
Canaccord Genuity initiated coverage of Core Scientific with a rating of Buy and set a new price target of $16.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/27/2025 | $22.00 | Outperform | Keefe Bruyette |
| 1/21/2025 | $24.00 | Buy | Craig Hallum |
| 11/15/2024 | $25.50 | Buy | ROTH MKM |
| 10/28/2024 | $19.00 | Buy | Jefferies |
| 9/25/2024 | $16.00 | Outperform | Macquarie |
| 9/23/2024 | $16.00 | Buy | Canaccord Genuity |
| 9/4/2024 | $16.00 | Buy | Needham |
| 7/17/2024 | $20.00 | Overweight | Cantor Fitzgerald |
4 - Core Scientific, Inc./tx (0001839341) (Issuer)
4 - Core Scientific, Inc./tx (0001839341) (Issuer)
4 - Core Scientific, Inc./tx (0001839341) (Issuer)
Core Scientific, Inc. (NASDAQ:CORZ), a leader in digital infrastructure for high-density colocation services and digital asset mining, today announced that Todd Becker will be stepping down from its Board of Directors, effective immediately. Mr. Becker joined the Board in January 2024 and has served as Chair of the Audit Committee. During his tenure, he provided critical leadership and oversight as Core Scientific completed two significant capital raises that materially improved the company's balance sheet, the hiring of a new Chief Financial Officer and supported its ongoing operational and strategic objectives following its emergence from bankruptcy. His financial acumen and disciplined
First Quarter 2025 Highlights On track to deliver 250MW of billable capacity to CoreWeave by the end of this year and anticipate entering 2026 with annualized colocation revenue of approximately $360 million. First tranche of 8MW of billable capacity at Denton to be delivered to CoreWeave by the end of this month and an additional approximately 40MW by the end of this quarter. Ended the quarter with a strong liquidity position, including $778.6 million in cash and cash equivalents and digital assets, maintaining financial flexibility to execute on strategic organic and inorganic growth opportunities. Core Scientific, Inc. (NASDAQ:CORZ), a leader in digital infrastructure for high-de
Core Scientific, Inc. (NASDAQ:CORZ) ("Core Scientific" or "the Company"), a leader in digital infrastructure for high-performance computing and bitcoin mining, today announced it will issue financial results for the Company's fiscal year 2025 first quarter after financial markets close on Wednesday, May 7, 2025. Management will host a conference call and live audio webcast to discuss the results at 3:30 p.m. Central Time. Hosting the call and webcast to review results for the first quarter 2025 will be Adam Sullivan, Chief Executive Officer, Jim Nygaard, Chief Financial Officer, and Jon Charbonneau, Vice President, Investor Relations. Conference Call and Webcast Event Summary Date: May 7
4 - Core Scientific, Inc./tx (0001839341) (Issuer)
4 - Core Scientific, Inc./tx (0001839341) (Issuer)
4 - Core Scientific, Inc./tx (0001839341) (Issuer)
Keefe Bruyette initiated coverage of Core Scientific with a rating of Outperform and set a new price target of $22.00
Craig Hallum initiated coverage of Core Scientific with a rating of Buy and set a new price target of $24.00
ROTH MKM initiated coverage of Core Scientific with a rating of Buy and set a new price target of $25.50
Industry Veteran Scott Brueggeman Joins Core Scientific as Chief Marketing Officer to Drive Market Expansion and Visibility Core Scientific, Inc. (NASDAQ:CORZ) ("Core Scientific" or "the Company"), a leader in digital infrastructure for high-performance computing and digital asset mining, today announced the appointment of Scott Brueggeman as Chief Marketing Officer. With over 20 years of experience in digital infrastructure and technology businesses, Brueggeman will play a pivotal role in strengthening the company's brand presence, driving growth, and expanding market opportunities. Brueggeman brings a proven track record of success in high-growth environments. Most recently, he served
8-K - Core Scientific, Inc./tx (0001839341) (Filer)
10-Q - Core Scientific, Inc./tx (0001839341) (Filer)
8-K - Core Scientific, Inc./tx (0001839341) (Filer)
First Quarter 2025 Highlights On track to deliver 250MW of billable capacity to CoreWeave by the end of this year and anticipate entering 2026 with annualized colocation revenue of approximately $360 million. First tranche of 8MW of billable capacity at Denton to be delivered to CoreWeave by the end of this month and an additional approximately 40MW by the end of this quarter. Ended the quarter with a strong liquidity position, including $778.6 million in cash and cash equivalents and digital assets, maintaining financial flexibility to execute on strategic organic and inorganic growth opportunities. Core Scientific, Inc. (NASDAQ:CORZ), a leader in digital infrastructure for high-de
Core Scientific, Inc. (NASDAQ:CORZ) ("Core Scientific" or "the Company"), a leader in digital infrastructure for high-performance computing and bitcoin mining, today announced it will issue financial results for the Company's fiscal year 2025 first quarter after financial markets close on Wednesday, May 7, 2025. Management will host a conference call and live audio webcast to discuss the results at 3:30 p.m. Central Time. Hosting the call and webcast to review results for the first quarter 2025 will be Adam Sullivan, Chief Executive Officer, Jim Nygaard, Chief Financial Officer, and Jon Charbonneau, Vice President, Investor Relations. Conference Call and Webcast Event Summary Date: May 7
Fourth Quarter 2024 Highlights Incurred net loss of $265.5 million due primarily to a $224.7 million non-cash mark-to-market adjustment to warrants and other contingent value right liabilities required by the significant year-over-year increase in our share price Reported operating loss of $39.8 million, a decrease of $43.7 million over fourth quarter 2023 Generated adjusted EBITDA of $13.3 million, a decrease of $43.4 million over fourth quarter 2023 Secured $625 million through a convertible note offering with favorable 0% interest terms Strengthened the balance sheet, ending the quarter with cash and cash equivalents of $836.2 million as of December 31, 2024 Earned 974
SC 13G - Core Scientific, Inc./tx (0001839341) (Subject)
SC 13D/A - Core Scientific, Inc./tx (0001839341) (Subject)
SC 13D/A - Core Scientific, Inc./tx (0001839341) (Subject)